According to a recent market study published by Growth Market Reports, titled, “Global Inhalation Devices Market by Type, By Indication, By Distribution Channel, By End-user, and By Region: Size, Share, Trends and Opportunity Analysis, 2016-2031”, the market was valued at US$ 48,052.9 Million in 2022 and is anticipated to expand at a growth rate of 4.9% by 2031.

Get Sample Report @ https://growthmarketreports.com/request-sample/5628

Inhalation devices are basically medical instruments that are utilizes to deliver medication to the lungs through the work of a person’s breathing. Several types of inhalation devices are available including the pressurized metered dose inhaler (pMDI), the dry powder inhaler (DPI), the soft mist inhaler (SMI), and others. As it minimizes the need for and the negative effects related to the use of injectables and oral medications, and inhalers are crucial for adhering to the stringent schedule necessary for these disorders. Several patients often misuse the freedom that comes with using inhalers by failing to adhere to the advised treatment plan and forgetting to stock up on refills before the previous one runs out, However, with the introduction of cutting-edge technology that assists in examining the patient's overall health, the way medicine is practiced has experienced significant changes. This is particularly so with the Internet of Things (IoT). An inhaler incorporates communication with a mobile app, such as Bluetooth, is referred to as a smart inhaler. These gadgets have sensors integrated into them to help record information about each use, including the time and date, and patient's location. Teva's ProAir Digihaler (albuterol sulfate) contains a use-tracking real-time sensor that syncs it to a mobile app, making it the first smart inhaler in the world to get FDA certification.

The Global Inhalation Devices Market has been segmented in terms of type, indication, distribution channel, end-user, and region. In terms of type, the Global Inhalation Devices Market is split into nasal sprays, metered dose inhalers (MDI), dry powder inhalers (DPI), and nebulizers. On the basis of indication, the market is fragmented into chronic obstructive pulmonary disease (COPD), asthma, nasal congestion, and others. In terms of distribution channel, the Global Inhalation Devices Market is split into online pharmacy and offline pharmacy. On the basis of end-user, the market is fragmented into hospitals, clinics, home care, and others. Considering regions, the market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

The COVID-19 pandemic has affected inhalation devices production and the import & export of raw materials and finished goods in various COVID-19-affected countries. This lockdown created a shortage of equipment and supply chain disruption. According to a study published in October 2020 titled, ’Impact of COVID-19 on people with asthma: a mixed-methods analysis from a United Kingdom-wide survey’, those who reported having COVID-19 used their inhalers frequently and had worse asthma management than those who did not. According to the article, ‘Influence of the First Wave of COVID-19 on Asthma Inhaler Prescriptions’, published in November 2021, the COVID-19 pandemic led to enormous demand for asthma inhalers, posing concerns. A significant rise in the number of inhalers was registered since March 2020 using the primary-care medical data of 614,700 asthma patients between January and June 2020.

Key Takeaways from the Study:

  • Players in the Global Inhalation Devices Market include AptarGroup, Inc., Recipharm AB, AstraZeneca, Cipla Limited, Lepu Medical Technology, Boehringer Ingelheim International GmbH, GSK plc., Catalent, Inc., and Others.

  • Growing awareness about respiratory health and the need for effective treatment options are expected to create opportunities in the coming years.

  • Based on type, the market is segmented into nasal sprays, metered dose inhalers (MDI), dry powder inhalers (DPI), and nebulizers. The metered dose inhalers (MDI) segment is expected to hold a considerable share of the market during the forecast period, as they are small, portable, and easy to handle. It releases a consistent amount of medicine. These inhalers usually contain 200 or 120 doses in one canister.

  • Based on indication, the market is segmented into chronic obstructive pulmonary disease (COPD), asthma, nasal congestion, and others. The chronic obstructive pulmonary disease (COPD) segment is expected to hold a considerable share of the market during the forecast period. The growth of the segment is attributed to the rising open-air causative agents, including contamination and allergens, along with the changing lifestyle. Additionally, the growing prevalence of COPD across the globe, mainly in developing countries with high smoking rates and air pollution, is expected to boost the segment in the coming years.

  • Based on distribution channel, the market is segmented into online pharmacy and offline pharmacy. The offline pharmacies segment is expected to hold a considerable share of the market during the forecast period. The offline pharmacy segment includes hospital and retail pharmacies. A hospital pharmacy is an integral department within the hospital that prepares, stores, and dispenses medicines and medical devices. Hospital pharmacists provide services to people admitted to hospitals.

  • Based on the end-user, the market is segmented into hospitals, clinics, home care, and others. The homecare segment is anticipated to expand at a significant CAGR during the forecast period. Homecare settings can offer several benefits for the patients or clients and their families, such as convenience, comfort, cost-effectiveness, personalization, continuity, quality, and satisfaction.

  • Based on regions, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for a significant share of the market in 2022. The market in Europe is expected to expand at a significant rate during the forecast period, due to the increasing number of chronic respiratory diseases among the people in the region. Additionally, the rising acceptance of smart inhalation devices and the rising demand for digital medical devices in Germany, the UK, and France are expected to drive the market in the region.

Report Scope:

Report Metric

Details

Market Value in 2022

US$ 48,052.9 Million

Market Growth Rate (from 2022 to 2031)

4.9%

Historical Data

2016 & 2021

Base Year

2022

Forecast Period

2023 – 2031

Units Considered

Value (US$ Million)

Market Segments

By Type, By Indication, By Distribution Channel, By End-user, and By Region

Key Companies Profiled

AptarGroup, Inc., Recipharm AB, AstraZeneca, Cipla Limited, Lepu Medical Technology, Boehringer Ingelheim International GmbH, GSK plc., Catalent, Inc., and Others.

Customization Scope

Report customization available on request

Pricing and Purchase Options

Avail of tailor-made purchase options to meet your research requirements.

Target Audience:

  • Supply-side: Vendor, Manufacturer, Distributors, Supplier, Retailer.

  • Regulatory Side: Concerned government authorities, and other approved regulatory bodies.